Table 4.
Baseline characteristics by third dose vaccine allocation and priming vaccine schedule, group C
|
Prime with ChAd/ChAd |
Prime with BNT/BNT |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| Control (n=114) | BNT half (n=117) | m1273 (n=112) | CVn (n=119) | Control (n=112) | BNT half (n=110) | m1273 (n=111) | CVn (n=106) | ||
| Age, years | |||||||||
| Mean (SD) | 64·0 (13·2) | 64·6 (13·6) | 63·8 (14·1) | 64·4 (13·5) | 63·6 (16·3) | 62·6 (17·3) | 63·0 (15·3) | 62·7 (16·4) | |
| Median (IQR) | 70·3 (54·4–75·1) | 71·0 (55·8–75·3) | 70·2 (53·0–75·3) | 70·3 (54·8–75·1) | 66·8 (51·9–78·0) | 64·4 (47·7–78·2) | 65·0 (50·3–75·5) | 63·4 (47·3–76·6) | |
| Intervals between first and second doses, days | 72·0 (65·0–77·0) | 74·0 (66·0–77·0) | 70·0 (63·0–77·0) | 72·0 (65·0–77·0) | 70·0 (45·0–76·0) | 60·5 (22·2–74·8) | 66·0 (23·0–76·0) | 66·0 (23·0–73·8) | |
| Intervals between second and third doses, days | 77·5 (73·0–85·0) | 78·0 (73·0–84·2) | 79·0 (74·0–86·0) | 78·0 (73·5–85·0) | 93·5 (87·0–116·0) | 107·5 (90·0–157·5) | 101·5 (89·0–152·2) | 98·0 (88·0–151·8) | |
| Age groups, years | |||||||||
| <70 | 54 (47·4%) | 55 (47·0%) | 55 (49·1%) | 58 (48·7%) | 60 (53·6%) | 62 (56·4%) | 62 (55·9%) | 58 (54·7%) | |
| ≥70 | 60 (52·6%) | 62 (53·0%) | 57 (50·9%) | 61 (51·3%) | 52 (46·4%) | 48 (43·6%) | 49 (44·1%) | 48 (45·3%) | |
| Gender | |||||||||
| Female | 47 (41·2%) | 48 (41·0%) | 45 (40·2%) | 54 (45·4%) | 60 (53·6%) | 52 (47·3%) | 63 (56·8%) | 56 (52·8%) | |
| Male | 67 (58·8%) | 69 (59·0%) | 67 (59·8%) | 65 (54·6%) | 52 (46·4%) | 58 (52·7%) | 48 (43·2%) | 50 (47·2%) | |
| Occupation | |||||||||
| Health worker | 29 (25·4%) | 28 (23·9%) | 26 (23·2%) | 26 (21·8%) | 48 (42·9%) | 58 (52·7%) | 59 (53·2%) | 55 (51·9%) | |
| Other | 85 (74·6%) | 89 (76·1%) | 85 (75·9%) | 92 (77·3%) | 64 (57·1%) | 52 (47·3%) | 52 (46·8%) | 51 (48·1%) | |
| Ethnicity | |||||||||
| White | 108 (94·7%) | 115 (98·3%) | 108 (96·4%) | 113 (95·0%) | 105 (92·9%) | 93 (84·5%) | 103 (92·8%) | 87 (82·1%) | |
| Black | 1 (0·9%) | 0 | 0 | 0 | 0 | 2 (1·8%) | 0 | 1 (0·9%) | |
| Asian | 2 (1·8%) | 1 (0·9%) | 2 (1·8%) | 5 (4·2%) | 7 (6·2%) | 9 (8·2%) | 4 (3·6%) | 14 (13·2%) | |
| Mixed | 1 (0·9%) | 0 | 1 (0·9%) | 0 | 1 (0·9%) | 3 (2·7%) | 3 (2·7%) | 2 (1·9%) | |
| Other | 1 (0·9%) | 0 | 0 | 0 | 0 | 2 (1·8%) | 0 | 1 (0·9%) | |
| Not given | 0 | 1 (0·9%) | 0 | 0 | 0 | 1 (0·9%) | 0 | 1 (0·9%) | |
| Comorbidities | |||||||||
| Cardiovascular | 39 (34·2%) | 35 (29·9%) | 36 (32·1%) | 36 (30·3%) | 43 (38·4%) | 35 (31·8%) | 29 (26·1%) | 35 (33·0%) | |
| Respiratory | 14 (12·3%) | 17 (14·5%) | 12 (10·7%) | 12 (10·1%) | 12 (10·6%) | 17 (15·5%) | 17 (15·3%) | 9 (8·5%) | |
| Diabetes | 5 (4·4%) | 4 (3·4%) | 7 (6·2%) | 11 (9·2%) | 7 (6·2%) | 11 (10·0%) | 3 (2·7%) | 8 (7·5%) | |
Data are median (IQR) or n (%), unless otherwise stated. There were three participants missing on occupation and five participants missing on ethnicity, which were not included in this table. ChAd=ChAdOx1 nCoV-19 vaccine, Oxford–AstraZeneca. Control=quadrivalent meningococcal conjugate vaccine. BNT=BNT162b2 vaccine, Pfizer–BioNTech. BNT half=half dose of BNT162b2 vaccine. m1273=mRNA1273 vaccine, Moderna. CVn=CVnCoV vaccine, Curevac.